Chuh, A., et al. “A Position Statement on the Management of Patients With Pityriasis Rosea.” JEADV 2016: 1-12.

Drago F, Broccolo F, and Rebora A. “Pityriasis Rosea: An Update With a Critical Appraisal of Its Possible Herpesviral Etiology.” J Am Acad Dermatol 61.2 Aug. 2009: 303-318.

Drago F, Broccolo F, et al. “Pregnancy Outcome in Patients With Pityriasis Rosea.” J Am Acad Dermatol 58.5 May 2008: S78-83.

Drago F, Ciccarese G, Javor S, and Parodi A. “Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature.” J Eur Acad Dermatol Venereol 30.3 Mar. 2016: 544-545.

Drago, F, Ciccarese G, Rebora A, Broccolo F, and Parodi A. “Pityriasis Rosea: A Comprehensive Classification.” Dermatology Apr. 21, 2016: 1-7.

Eisman S, and Sinclair R. “Pityriasis Rosea.” BMJ 351 (2015): 1-6.

Honi BA, Keeling JH, Lewis CW, Thompson IM. “A pityriasis rosea-like eruption secondary to bacillus Calmette-Guérin therapy for bladder cancer.” Cutis 57.6 June 1996: 447-450.

Kempf W, Adams V, Kleinhans M, Burg G, Panizzon RG, Campadelli-Fiume G, et al. “Pityriasis rosea is not associated with human herpesvirus 7.” Arch Dermatol 135 (1999): 1070–1072.

Mahajan, Khushbu, et al. “Pityriasis Rosea: An Update of Etiopathogenesis and Management of Difficult Aspects.” Indian J Dermatol 61.4 July-Aug 2016: 375-384.

Pandhi D, Singal A, Verma P, Sharma R.”The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial.” Indian J Dermatol Venereol Leprol 80.1 Jan-Feb 2014: 36-40. doi: 10.4103/0378-6323.125484.

“Pityriasis Rosea.” American Academy of Dermatology. .

Rasi A, Tajziehchi L, Savabi-Nasab S. “Oral erythromycin is ineffective in the treatment of pityriasis rosea.” J Drugs Dermatol 7 (2008): 35-38.

Sarvajnamurthy Sacchidanand, Suryanarayan Shwetha, Dipali D. Malvankar, and Mallaiah Mallikarjuna. “Polymorphic pityriasis rosea precipitating psoriasis.” Indian Dermatol Online J 4.1 Jan-Mar 2013: 63-64.